Develops and licenses the AlivaMab transgenic mouse platform for discovering human therapeutic antibodies and antibody-derived drug candidates
Develops and licenses the AlivaMab transgenic mouse platform for discovering human therapeutic antibodies and antibody-derived drug candidates. The platform is used by pharmaceutical and biotechnology companies and academic institutions; related discovery services are provided by sister company AlivaMab Biologics.